Pathological Characteristics, PCNA Labeling Index and DNA Index in Prognostic Evaluation of Patients with Moderately Differentiated Hepatocellular Carcinoma

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2002 Nov 20

PMID 12439921

Citations 10

Authors

Wen-Jiao Zeng

Guo-Yuan Liu

Jie Xu

Xin-DA Zhou

Yue-E Zhang

Nong Zhang

Affiliations

Soon will be listed here.

Abstract

Aim: To study the relationship between prognosis and pathological characteristics, proliferating cell nuclear antigen labeling index (PCNA-LI) and DNA index (DI) in patients with moderately differentiated hepatocellular carcinoma(HCC).

Methods: 51 cases of moderately differentiated HCC were analyzed with respect to the relation between their clinical follow-up data and pathological characteristics. Meanwhile, PCNA-LI of HCC cells was detected by immunohistochemistry assay and DI was measured by Feulgen staining and automatic image analysis technique.

Results: Patients with a single tumor nodule, less than 5 cm in diameter, no tumor emboli, no daughter nodules and necrosis had relatively better prognosis; patients with euploidy HCC had better prognosis than those with aneuploidy; among the aneuploidy patients those with DI<1.5 had better prognosis than the cases with DI>1.5; The higher the PCNA-LI, the worse would be the prognosis. The increase in DI was correlated with the increase in PCNA-LI, and both of them were correlated with the pathological changes of the tumor.

Conclusion: A composite analysis of the pathological characteristics of tumor tissue, DI and PCNA-LI might be useful in predicting the prognosis of HCC patients.

Citing Articles

Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review).

Wang C, Zhang H, Liu Y, Wang Y, Hu H, Wang G Oncol Lett. 2023; 25(6):230.

PMID: 37153060 PMC: 10157608. DOI: 10.3892/ol.2023.13816.

β-carotene Regulates the Murine Liver Microenvironment of a Metastatic Neuroblastoma.

Lim J, Kim Y, Kim Y J Cancer Prev. 2014; 18(4):337-45.

PMID: 25337563 PMC: 4189442. DOI: 10.15430/jcp.2013.18.4.337.

Asymmetric cell division in polyploid giant cancer cells and low eukaryotic cells.

Zhang D, Wang Y, Zhang S Biomed Res Int. 2014; 2014:432652.

PMID: 25045675 PMC: 4089188. DOI: 10.1155/2014/432652.

Expression and clinical significance of NET-1 and PCNA in hepatocellular carcinoma.

Shen S, Li K, Zhu N, Nakao A Med Oncol. 2008; 25(3):341-5.

PMID: 18214716 DOI: 10.1007/s12032-008-9042-6.

Serum tumor markers for detection of hepatocellular carcinoma.

Zhou L, Liu J, Luo F World J Gastroenterol. 2006; 12(8):1175-81.

PMID: 16534867 PMC: 4124425. DOI: 10.3748/wjg.v12.i8.1175.

References

Gschwendtner A, Fend F, HOFFMANN Y, Krugmann J, Klingler P, Mairinger T . DNA-ploidy analysis correlates with the histogenetic classification of thymic epithelial tumours. J Pathol. 2000; 189(4):576-80. DOI: 10.1002/(SICI)1096-9896(199912)189:4<576::AID-PATH455>3.0.CO;2-L. View

Fan J, Wu Z, Tang Z, Zhou J, Qiu S, Ma Z . Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J Gastroenterol. 2002; 7(1):28-32. PMC: 4688696. DOI: 10.3748/wjg.v7.i1.28. View

Aoyagi Y, Mita Y, Suda T, Kawai K, Kuroiwa T, Igarashi M . The fucosylation index of serum alpha-fetoprotein as useful prognostic factor in patients with hepatocellular carcinoma in special reference to chronological changes. Hepatol Res. 2002; 23(4):287. DOI: 10.1016/s1386-6346(01)00184-x. View

Donato M, Arosio E, Del Ninno E, Ronchi G, Lampertico P, Morabito A . High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. Hepatology. 2001; 34(3):523-8. DOI: 10.1053/jhep.2001.26820. View

Closset J, Van de Stadt J, Delhaye M, El NAkadi I, LAMBILLIOTTE J, Gelin M . Hepatocellular carcinoma: surgical treatment and prognostic variables in 56 patients. Hepatogastroenterology. 1999; 46(29):2914-8. View

Ohmiya N, Matsumoto S, Yamamoto H, Baranovskaya S, Malkhosyan S, Perucho M . Germline and somatic mutations in hMSH6 and hMSH3 in gastrointestinal cancers of the microsatellite mutator phenotype. Gene. 2001; 272(1-2):301-13. DOI: 10.1016/s0378-1119(01)00517-0. View

Yoong K, Afford S, Jones R, Aujla P, Qin S, Price K . Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology. 1999; 30(1):100-11. DOI: 10.1002/hep.510300147. View

Yoong K, McNab G, Hubscher S, Adams D . Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol. 1998; 160(8):3978-88. View

Mastronardi L, Guiducci A, Buttaro F, Cristallini E, Puzzilli F, Maira G . Relationships among DNA Index, S-Phase, and invasive behavior in anterior pituitary adenomas. A cytometric study of 61 cases with Feulgen-positive DNA analysis. Surg Neurol. 2001; 56(1):27-32. DOI: 10.1016/s0090-3019(01)00455-4. View

10.

Kruslin B, Visnjic A, Cizmic A, Tomicic I, Kos M, Jukic S . DNA ploidy analysis and cell proliferation in congenital sacrococcygeal teratomas. Cancer. 2000; 89(4):932-7. DOI: 10.1002/1097-0142(20000815)89:4<932::aid-cncr29>3.0.co;2-0. View

11.

Celis J, Madsen P, Celis A, Nielsen H, Gesser B . Cyclin (PCNA, auxiliary protein of DNA polymerase delta) is a central component of the pathway(s) leading to DNA replication and cell division. FEBS Lett. 1987; 220(1):1-7. DOI: 10.1016/0014-5793(87)80865-7. View

12.

Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J . Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000; 356(9232):802-7. DOI: 10.1016/S0140-6736(00)02654-4. View

13.

Brew K, Dinakarpandian D, Nagase H . Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000; 1477(1-2):267-83. DOI: 10.1016/s0167-4838(99)00279-4. View

14.

Giannelli G, Pierri F, Trerotoli P, Marinosci F, Serio G, Schiraldi O . Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases. Hepatol Res. 2002; 24(1):50. DOI: 10.1016/s1386-6346(02)00027-x. View

15.

Zhao W, Ma Z, Zhou X, Feng Y . Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol. 2002; 8(2):237-42. PMC: 4658358. DOI: 10.3748/wjg.v8.i2.237. View

16.

Wu P, Lau V, Fang J, Lai V, Lai C, Lau J . Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma. Liver. 1999; 19(5):444-51. DOI: 10.1111/j.1478-3231.1999.tb00076.x. View

17.

Davidson B, Goldberg I, Gotlieb W, Kopolovic J, Ben-Baruch G, Nesland J . The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol. 2002; 187(1-2):39-45. DOI: 10.1016/s0303-7207(01)00709-2. View

18.

Tang Z . Hepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol. 2002; 7(4):445-54. PMC: 4688653. DOI: 10.3748/wjg.v7.i4.445. View

19.

Martin G, Halwani F, Shibata H, Meterissian S . Value of DNA ploidy and S-phase fraction as prognostic factors in stage III cutaneous melanoma. Can J Surg. 2000; 43(1):29-34. PMC: 3788923. View

20.

Westermarck J, Kahari V . Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999; 13(8):781-92. View